CSPC PHARMACEUTICAL GROUP LIMITED
石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

PACLITAXEL FOR INJECTION (ALBUMIN-BOUND) (II) RECEIVES MARKETING APPROVAL

The Board of Directors (the "**Board**") of CSPC Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that Paclitaxel for Injection (Albumin-Bound) (II) (100mg) (the "**Product**") developed by the Group has received marketing approval from the National Medical Products Administration of the People's Republic of China, making it the global first quick-dissolving albumin-bound paclitaxel formulation.

The Product is an innovative anti-tumor nano-formulation independently developed by the Group. It adopts an innovative formulation and preparation process, with related patents having been granted in major countries and regions including China, the United States and Europe. It is indicated for the treatment of metastatic breast cancer after failure of combination chemotherapy or breast cancer relapse within 6 months of adjuvant chemotherapy (prior chemotherapy regimens should have included an anthracycline unless clinically contraindicated).

The results of a multicenter, randomised, double-blind pivotal Phase III clinical study showed that the Product demonstrated more significant efficacy benefits in patients with breast cancer compared with Paclitaxel for Injection (Albumin-Bound): the between-group ratios of objective response rate as assessed by the Independent Review Committee (IRC) and investigators were 1.38 (95% CI: 1.040, 1.842) and 1.33 (95% CI: 1.020, 1.745), respectively, both meeting the superiority criteria. The risk of disease progression or death was reduced by 27% (hazard ratio ("**HR**") for progression-free survival (PFS) = 0.73); and the risk of death was reduced by 33% (HR for overall survival (OS) = 0.67). Compared with the control drug, the Product reduced the risk of rash incidence by 62%, demonstrating a better safety profile in clinical use, which helps improve patients' quality of life and enhance medication adherence. At the same time, the reconstitution time was shortened by 82%, significantly improving convenience of clinical use.

The marketing approval of the Product could effectively address the clinical treatment shortcomings of existing taxane drugs, further enrich clinical medication regimens, provide higher-quality treatment options, and enhance the Group's competitiveness in the field of anti-tumor chemotherapy drugs.

By Order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 15 June 2026

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping, Mr. QU Zhiyong and Mr. ZHANG Yiwei as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.